# Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

> **NCT03785210** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 22 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatocellular Cancer
- Metastatic Pancreatic Cancer
- Metastatic Colorectal Cancer
- Liver Metastasis

## Interventions

- **DRUG:** nivolumab
- **DRUG:** tadalafil
- **DRUG:** oral vancomycin

## Key facts

- **NCT ID:** NCT03785210
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-05
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Study was terminated due to poor accrual.
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785210, "Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03785210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*